SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma trades higher on getting USFDA’s final approval for Loratadine Tablets

25 Nov 2024 Evaluate

Marksans Pharma is currently trading at Rs. 313.90, up by 5.35 points or 1.73% from its previous closing of Rs. 308.55 on the BSE.

The scrip opened at Rs. 318.00 and has touched a high and low of Rs. 318.70 and Rs. 310.00 respectively. So far 51508 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 328.35 on 20-Sep-2024 and a 52 week low of Rs. 126.05 on 14-Mar-2024.

Last one week high and low of the scrip stood at Rs. 319.00 and Rs. 297.25 respectively. The current market cap of the company is Rs. 14190.82 crore.

The promoters holding in the company stood at 43.87%, while Institutions and Non-Institutions held 25.41% and 30.71% respectively.

Marksans Pharma has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.

They are indicated for the treatment of allergic rhinitis caused by pollen and upper respiratory tract allergy for over-the-counter (OTC) use. This product is generic version of Clartin tablet in the same strength of Bayer Healthcare. Loratadine is an antihistamine that treats symptoms such as itching, runny nose, watery eyes, and sneezing from ‘hay fever’ and other allergies.

Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.

Marksans Pharma Share Price

188.85 4.20 (2.27%)
04-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.10
Dr. Reddys Lab 1287.95
Cipla 1334.85
Zydus Lifesciences 901.65
Lupin 2350.95
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×